OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Bought by Brown Advisory Inc.

Brown Advisory Inc. lifted its stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 1.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,628,779 shares of the company's stock after acquiring an additional 25,337 shares during the period. Brown Advisory Inc. owned 6.98% of OrthoPediatrics worth $52,952,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in KIDS. Blue Trust Inc. lifted its position in shares of OrthoPediatrics by 1.5% during the fourth quarter. Blue Trust Inc. now owns 28,670 shares of the company's stock valued at $917,000 after buying an additional 421 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in OrthoPediatrics by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company's stock valued at $3,895,000 after acquiring an additional 549 shares in the last quarter. Swiss National Bank grew its holdings in OrthoPediatrics by 2.4% in the third quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,232,000 after purchasing an additional 900 shares during the last quarter. CWM LLC increased its position in shares of OrthoPediatrics by 16,283.3% during the fourth quarter. CWM LLC now owns 983 shares of the company's stock worth $32,000 after purchasing an additional 977 shares in the last quarter. Finally, RiverPark Advisors LLC acquired a new stake in shares of OrthoPediatrics in the 3rd quarter worth $35,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Stock Performance

Shares of KIDS stock traded up $0.23 during mid-day trading on Friday, reaching $32.02. The stock had a trading volume of 80,412 shares, compared to its average volume of 157,222. The company has a current ratio of 4.45, a quick ratio of 1.99 and a debt-to-equity ratio of 0.03. OrthoPediatrics Corp. has a 1-year low of $23.10 and a 1-year high of $48.47. The firm has a market cap of $763.00 million, a price-to-earnings ratio of -33.35 and a beta of 1.16. The business's fifty day moving average is $29.48 and its 200-day moving average is $29.48.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. The company had revenue of $37.61 million during the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative net margin of 13.58% and a negative return on equity of 5.12%. On average, research analysts forecast that OrthoPediatrics Corp. will post -1.2 earnings per share for the current year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, insider Joseph W. Hauser sold 2,903 shares of OrthoPediatrics stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total transaction of $81,458.18. Following the completion of the transaction, the insider now owns 52,858 shares in the company, valued at approximately $1,483,195.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Joseph W. Hauser sold 2,903 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $28.06, for a total transaction of $81,458.18. Following the sale, the insider now owns 52,858 shares of the company's stock, valued at approximately $1,483,195.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 2,741 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total transaction of $75,624.19. Following the completion of the transaction, the general counsel now owns 52,403 shares of the company's stock, valued at $1,445,798.77. The disclosure for this sale can be found here. Insiders sold 17,253 shares of company stock worth $477,375 over the last three months. Company insiders own 31.80% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on KIDS shares. Truist Financial upped their target price on OrthoPediatrics from $35.00 to $38.00 and gave the company a "hold" rating in a research report on Wednesday, May 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $50.00 price objective on shares of OrthoPediatrics in a research report on Tuesday, May 7th. Finally, Needham & Company LLC boosted their target price on shares of OrthoPediatrics from $37.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, May 7th.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.